Dieter Schapfel - Enzo Biochem Chief Medical Director of Enzo Clinical Labs
| ENZ Stock | USD 1.06 0.01 0.95% |
Director
Dr. Dieter Schapfel, M.D., is Chief Medical Director, Enzo Clinical Labs of the company. Dr. Schapfel served as Medical Director of Pathology at Southside HospitalNorth ShoreLong Island Jewish Health System from 2006 to 2012. Dr. Schapfel served as a staff pathologist at Huntington Hospital from January 2004 to June 2006. Dr. Schapfel served as Director of Pathology and Medical Affairs and the College of American Pathologists Director of Pathology, Dublin, Ireland and Farmingdale, NY for Icon Laboratories from February 2002 to October 2003. Dr. Schapfel is a graduate of the State University of New York at Stony Brook, College of Medicine, where he also served his residency. He is a diplomat of the American Board of Pathology with certification in Anatomic and Clinical Pathology and is also a diplomat of The National Board of Medical Examiners. since 2014.
| Age | 57 |
| Tenure | 10 years |
| Phone | 631 755 5500 |
| Web | https://www.enzo.com |
Enzo Biochem Management Efficiency
The company has Return on Asset of (0.1653) % which means that on every $100 spent on assets, it lost $0.1653. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4501) %, meaning that it generated no profit with money invested by stockholders. Enzo Biochem's management efficiency ratios could be used to measure how well Enzo Biochem manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | DIRECTOR Age | ||
| MS MD | Sera Prognostics | 71 | |
| Claudette Chan | Fonar | 86 | |
| Tina Nova | Exagen Inc | 70 | |
| Daniel Culver | Fonar | N/A | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.17 |
Enzo Biochem Leadership Team
Elected by the shareholders, the Enzo Biochem's board of directors comprises two types of representatives: Enzo Biochem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enzo. The board's role is to monitor Enzo Biochem's management team and ensure that shareholders' interests are well served. Enzo Biochem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enzo Biochem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dieter MD, Chief Labs | ||
| Hamid Erfanian, Chief Executive Officer, Director | ||
| Barry Weiner, President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director | ||
| Mary Tagliaferri, Lead Independent Director | ||
| Dov Perlysky, Lead Independent Director | ||
| Bruce Dey, Vice President - Sales and Marketing of Enzo Clinical Labs | ||
| Ian Walters, Independent Director | ||
| Matthew Kupferberg, General Secretary | ||
| David Bench, Chief Financial Officer, Senior Vice President, Treasurer, Corporate Secretary | ||
| Peter Clemens, Director | ||
| Bruce Hanna, Independent Director | ||
| Patricia CPA, Interim Officer | ||
| Rebecca Fischer, Independent Director | ||
| Elazar Rabbani, Chairman of the Board, Chief Executive Officer, Secretary | ||
| Fabian Blank, Director | ||
| Bradley Radoff, Independent Director | ||
| Dieter Schapfel, Chief Medical Director of Enzo Clinical Labs | ||
| Kara Cannon, Corporate Vice President - Commercial Operations |
Enzo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enzo Biochem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | 0.99 % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 727.02 K | ||||
| Shares Outstanding | 51.23 M | ||||
| Shares Owned By Insiders | 24.19 % | ||||
| Shares Owned By Institutions | 37.49 % | ||||
| Number Of Shares Shorted | 676.7 K | ||||
| Price To Earning | 26.60 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enzo Biochem offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enzo Biochem's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enzo Biochem Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enzo Biochem Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enzo Biochem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Enzo Stock please use our How to Invest in Enzo Biochem guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Enzo Stock analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Enzo Biochem's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enzo Biochem. If investors know Enzo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enzo Biochem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enzo Biochem is measured differently than its book value, which is the value of Enzo that is recorded on the company's balance sheet. Investors also form their own opinion of Enzo Biochem's value that differs from its market value or its book value, called intrinsic value, which is Enzo Biochem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enzo Biochem's market value can be influenced by many factors that don't directly affect Enzo Biochem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enzo Biochem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enzo Biochem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enzo Biochem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.